Original Research ARTICLE
Probiotic Lactobacillus sakei proBio-65 Extract Ameliorates the Severity of Imiquimod Induced Psoriasis-Like Skin Inflammation in a Mouse Model
- 1Department of Applied Microbiology and Biotechnology, School of Biotechnology, Yeungnam University, Gyeongsan, South Korea
- 2Department of Energy and Materials Engineering, Dongguk University, Seoul, South Korea
- 3Department of Biological Engineering, Inha University, Incheon, South Korea
- 4Department of Biochemistry, Yeungnam University, Gyeongsan, South Korea
- 5National Science Museum, Ministry of Science, ICT and Future Planning, Daejeon, South Korea
This study was designed to evaluate the protective effect of ethanol extract (SEL001) isolated from a potent probiotic strain Lactobacillus sakei proBio-65 on imiquimod (IMQ)-induced psoriasis-like skin inflammation in a mouse model. Histopathological and histomorphometrical changes in the ear and dorsal skin tissues were observed under hematoxylin and eosin stain for general histopathological architectures or Masson’s trichrome stain for collagen fibers. The expression profile of psoriasis-associated specific genes was determined using Real-Time PCR analysis. As a result, topical application of IMQ resulted in a significant increase of mean total and epithelial (epidermis) thicknesses, the number of inflammatory cells infiltrated in the dermis, and the decrease of dermis collagen fiber occupied regions in the ear tissues of IMQ and IMQ plus vaseline treated groups when compared to the intact control group. A significant increase of epithelial thickness and number of inflammatory cells infiltrated in the dermis of dorsal skin tissues were also noticed in IMQ and IMQ plus vaseline treated groups as compared to the intact control group, suggesting classic IMQ-induced hypersensitive psoriasis. IMQ-induced hypersensitive psoriasis related histopathological changes to the ear and dorsal skin tissues were significantly inhibited by the treatment of a standard drug clobetasol and SEL001. Further, mRNA expression analysis indicated a significant increase in gene expression levels of pro-inflammatory cytokines, including IL-19, IL-17A, and IL-23 in IMQ and IMQ plus vaseline treated groups than that of the control. Clobetasol and SEL001 treated groups resulted in a lower gene expression level of IL-19, IL-17A, and IL-23 as compared to IMQ and IMQ plus vaseline treated groups. These results enforce that SEL001 could be a novel treatment for psoriasis and an alternative to other drugs that pose a number of side effects on the skin.
The skin is one of the vital organs of the body that serves as a barrier from the outside environment. Psoriasis is a chronic skin disorder with unknown trigger, which is characterized by inflammation, thickening, and abnormal epidermal proliferation with up to 4% of prevalence in the general population (Griffiths and Barker, 2007). The pathogenesis of psoriasis is multifactorial and, as a perpetual incendiary skin issue, irregularity amongst pro- and anti-inflammatory mediators may play a vital part in the development and progression of this skin disorder (Li et al., 2016). Due to its incomplete etiology, there is still no permanent cure; however, genetic predisposition and environments stimuli might have a disease causing role. While the pathogenesis of psoriasis is not fully elucidated, it is extensively putative that pro-inflammatory cytokines have a key role in both development and maintenance of psoriatic lesions. A number of studies have reported the presence of immune-derived cytokines in psoriatic skin lesions and serum, suggesting their role in the pathogenesis of psoriasis (Kagami et al., 2010; Res et al., 2010; Zhang et al., 2010; Mudigonda et al., 2012; Tokura, 2012; Yoo et al., 2012; El Malki et al., 2013; Wang et al., 2013). Specifically, tissue alterations seen in psoriasis are driven by the exaggerated production of pro-inflammatory cytokines and the lesion development is critically dependent on IL-23 and IL-17 (Lee et al., 2004; Piskin et al., 2006; van der Fits et al., 2009). One of the pro-inflammatory cytokines, IL-19 has a key role in psoriatic pathogenesis and upregulates in psoriatic lesions during disease progression (Li et al., 2005), thus, controlling the level of these pro-inflammatory cytokines is necessary to treat this chronic disease.
The effect of the concurrent presence of IL-17 and IL-19 in psoriasis lesions might have impact on various levels of the pathogenic progression. The two cytokines upregulate the expression of β-defensins and S100A proteins thereby increases the antibacterial competence of keratinocytes. Moreover, their role in impeding infections may uphold the process to infiltrate immune cells to skin and increase the inflammation (Wolf et al., 2008). The process could be further regulated by tight coordination of IL-19 and IL-17 which in turn could attract particular T-helper type 1-cells, dendritic cells and neutrophilic granulocytes thereby directly increasing the secretion of chemokines. In addition, IL-19 and IL-17 promote the maintenance and effector function of T helper type 17-cells synergistically through the production of several mediators. Of note, T helper type 17-cells are critical for pathogenicity, IL-23 drives their proliferation, survival, and cytokine production (Ouyang et al., 2008). In addition, IL-19 and IL-17 are known to induce other interleukins which contributes to the psoriasis typical epidermal alterations. Topical application of IMQ, a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder (van der Fits et al., 2009), and has been used as activator for valuable psoriasis animal model (Qin et al., 2014; Bai et al., 2016). Additionally, psoriasis may be linked with genuine comorbidities, for example, metabolic disorder and cardiovascular sickness, likely mirroring a systemic provocative part of the infection (Perera et al., 2012). At present, there are a number of temporary treatments for psoriasis ranging from tropical medicine, heliotherapy, and systematic to biological treatments (Gustafson et al., 2013). Nevertheless, the outcome of these treatments may result in severe side effects, thus, demands a much safer treatment to render this disease.
Probiotics are known as beneficial microorganisms that, when administered in adequate amounts, confer health benefits to the host (Joint FAO/WHO, 2001). The effect of probiotics on the skin could be mediated by the modulation of both the innate and the adaptive immune responses in the host. Modulation of an immune system is one of the beneficial effects of probiotics in human health. Recently, we reported that oral administration of heat-killed Lactobacillus sakei proBio65 inhibited immunoglobulin E-mediated histamine and β-hexosaminidase in NC/Nga mice, suggesting that L. sakei has an inhibitory effect on atopic dermatitis-like skin lesion (Park et al., 2008; Kim et al., 2013). Oral administration of L. casei has been seen to reduce antigen-specific skin inflammation by controlling the size of the CD8+ effector pool (Chapat et al., 2004). In addition, L. casei DN-114001 alleviates T-cell mediated skin inflammation (Hacini-Rachinel et al., 2009). Recently, L. pentosus GML-77 has been seen to inhibit skin lesions in IMQ-induced psoriasis in mice (Wu et al., 2017).
Use of probiotics and their cellular components in preventive medicine to maintain a healthy function is well documented (Matsumoto et al., 2005; Tojo et al., 2014). Probiotics have been proposed as therapeutic agents in various pathological conditions, including intestinal chronic inflammation, atopic dermatitis and gut homeostasis (Park et al., 2014; Tojo et al., 2014; Plaza-Díaz et al., 2017). Previously, we confirmed the therapeutic potential of SEL001 like products of plant and microbial origin in vitro and in vivo using a diabetic animal model (Shukla et al., 2011; Bajpai et al., 2016). Various studies have also shown that probiotics, such as L. sakei probio65 exhibit a wide range of pharmacological effects such as anti-atopic dermatitis in animals and humans (Park et al., 2008, 2014; Kim and Pyo, 2012; Kim et al., 2013, 2015c).
Although a number of studies have emphasized the therapeutic role of probiotics in various inflammatory conditions, there is no report available on the anti-inflammatory effects of SEL001 of probiotic origin in a psoriasis model of inflammation. Since the IMQ-induced psoriasis model highly resembles human psoriasis lesions (van der Fits et al., 2009), in this study, we investigated the effect of topical application of SEL001, a probiotic product isolated from L. sakei proBio65 in an IMQ-induced psoriasis mouse model.
Materials and Methods
Preparation of SEL001
To prepare the ethanolic extract of Lactobacillus sakei Probio65 hereby called SEL001, 48 h grown culture of strain L. sakei probio65 was mixed with ethanol (1:2 ratio) and the flask containing mixture of bacterial culture and ethanol was incubated at 150 rpm for 6 h at room temperature. Following the incubation, the mixture was centrifuged (8,000 g for 10 min) and the cell pellet was discarded. Resulting supernatant was filter sterilized and subjected to freeze drying until get a dry-powdered material, which was served as SEL001.
Chemical Composition Analysis of SEL001
Gas chromatography–mass spectrometry (GC–MS) was explored to identify the chemical composition of SEL001. Briefly, dried SEL001 derived from the probiotic strain L. sakei probio65 was dissolved in 95% v/v methanol and two microliter of this solution was injected for GC-MS analysis. The protocol was followed as reported by Ravi et al. (2013).
Thirty ICR mice of 6 weeks age were occupied from Samtaco Bio Co. (Korea), and were kept in cages at constant levels of temperature and humidity on 12 h light/dark cycles. The animals were acclimatized for 1 week and their backs were shaved using pet electric shaver (GSAK CO., LTD., Korea). The animals had free access to water and feed throughout the trial. Animal management and institutional approval for research protocols were supported and approved by the Animal Ethical Committee of the Yeungnam University (YNU-ANETCOMM-2016-00123), Gyeongsan, Korea.
IMQ-Induced Psoriasis Model and Treatment
The mice were divided into five groups; a control group, an IMQ group, an IMQ+vaseline group, an IMQ-clobetasol group, and an IMQ+SEL001. Each group contains 6 mice and were housed as 2 mice per cage.
In this study a total of four topical treatments were used such as, IMQ, vaseline, clobetasol, and SEL001. IMQ was used to induce psoriasis like skin inflammation in mouse mode. Further, the treatment groups received vaseline, clobetasol and SEL001 topically 1 h before topical application of IMQ. Clobetasol propionate, a corticosteroid drug is used to treat various skin diseases, including psoriasis, therefore, it was used a gold standard, and SEL001 was used as a test sample against IMQ-induced psoriasis. Except for the control group, all other groups received a daily dose of 62.5 mg of 5% IMQ cream/cm2 (Aldara; MEDA AS) applied their backs and 20 mg on the right ear once a day for six consecutive days as previously described (van der Fits et al., 2009; Nadeem et al., 2015; Rather et al., 2016). Further, IMQ+vaseline group received a daily dose of 62.5 mg of 5% IMQ cream plus vaseline cream (80 mg/cm2 on back and 20 mg on the right ear); IMQ plus clobetasol group received a daily dose of 62.5 mg of 5% IMQ cream plus clobetasol (80 mg/cm2 on back and 20 mg on the right ear), and IMQ plus SEL001 group received a daily dose of 62.5 mg of 5% IMQ cream plus SEL001 (50 mg/cm2 on back and 10 mg on the right ear).
Scoring of Skin Inflammation Severity
On days 0, 2, 4, and 6, all animas were assessed using 2 elements of the Psoriasis Area Severity Index (PASI), to consign a score of 0–4 (0, none; 1, moderate; 3, severe; 4, very severe) for both erythema and scaling parameters. Further, back skin and ear thickness were measured by using electronic caliper (Shenzhen Liweihui Technology Co., Ltd., China). After day 6, animals were euthanized and the shaved skin area of the back and ear was excised. Two lesions of the skin of each mouse were taken for histological and mRNA expression analysis.
Approximated regions of an individual ear and dorsal skin tissues were sampled and they were crossly trimmed. All trimmed ear and dorsal skin tissues were re-fixed in 10% neutral buffered formalin (NBF), again for 24 h. After paraffin embedding, 3–4 μm sections were prepared. Representative sections were stained with hematoxylin and eosin (HE) for general histological architectures or Masson’s trichrome (MT) for collagen fibers in the dermis of the ear and dorsal back skin tissues (Kim et al., 2015a; Bai et al., 2016). The histological profiles of individual cross trimmed ear and dorsal skin tissues were observed under a light microscope (Model Eclipse 80i, Nikon, Tokyo, Japan). Histological evaluation was performed on the two fields in each part of the ear and dorsal skin tissues; consequently, six histological fields of an ear and dorsal back skin tissues in each group were considered for further histomorphometric analysis. The histopathological analysis was done by the histopathologist who was unaware of group distribution. To observe more detailed changes, mean total and epithelial thicknesses of ear and dorsal skin tissues (μm), mean numbers of inflammatory cells infiltrated in dermis of ear and dorsal skin tissues (cells/mm2 of dermis) and mean collagen fiber occupied regions in dermis of ear and dorsal skin tissues (%/mm2 of dermis) were calculated using a computer-based automated image analyzer (iSolution FL ver 9.1, IMT i-solution Inc., Vancouver, QC, Canada) according to our previously established methods (Qin et al., 2014; Kim et al., 2015b; Bai et al., 2016). At least five repeated measurements were considered to calculate each mean histomorphometric value, whenever possible, in this histopathological evaluation.
The data obtained were analyzed by one-way ANOVA test followed by least significant differences (LSD) multi-comparison test to determine which pairs of group comparison were significantly different. Differences were considered significant at p < 0.05.
Quantitative Real-Time (RT) Reverse Transcriptase Polymerase Chain Reaction (PCR)
The extraction of RNA was done using TrizolTM reagent (Invitrogen, United States) following manufacturer’s instructions. The extracted RNA was diluted in RNase-free water and quantified using Nano Drop by measuring the absorbance at 260 and 280 nm. Further, 1 μg of RNA was converted to cDNA using Maxime RT premix (iNtRON Biotechnology). Transcription levels of genes were quantitatively determined using RT-PCR (Stratagene 246 mix 3000p QPCR System, Agilent Technologies, Santa Clara, CA, United States) by employing power SYBR green (Roche Diagnostics Gmbh, Mannheim, Germany). The PCR reactions for each sample were run in duplicate, and for every gene, the transcription levels were normalized with β-actin. The primers used in this study were purchased from Microgen (Korea).
Chemical Composition of SEL001
The GC–MS analysis of ethanolic extract of a probiotic strain L. sakei probio65 (SEL001) resulted in the identification of various compounds which included organic acids, amino acids, phenols, imidazole derivatives, and sugar alcohols along with some other organic compounds. The major composition of the SEL001 contained D-lactic acid (33.86%), propanoic acid (16.65%), glycerol (16.6%), L-lactic acid (6.03%), myo-inositol (1.86%), 1,3-butandiol (1.35%), 4-(methylsulfanylphenyl) carbamic acid (1.32%), 3,6-dioxa-2,7-disilaoctane (1.31%), pyrrolo[1,2-1] pyrazine-1,4-dione (1.26%), and valine (1.12%).
Erythema and Scaling
The severity of psoriasis during the 6-day trial was scored on 0, 2nd, 4th and 6th day following Psoriasis Area Severity Index (PASI). By applying IMQ on dorsal skin, psoriasis-like skin became apparent on second day onward. No significant changes in skin condition were seen on the second day in groups applied with vaseline, clobetasol or SEL001. However, from day three onward, erythema and scales were more visible. The erythema and scaling on mice back showed a dramatic increase in all groups as seen on day 4. However, a significant increase in erythema and scaling scores was seen in IMQ group when compared to control. In case of IMQ+vaseline group, a steady rate in erythema and slight decrease in scaling was observed from day 4 to day 6. In case of IMQ+clobetasol and IMQ+SEL001 the erythema scores were significantly less when compared to IMQ group (p < 0.01), and the scaling scores significantly decreased from day 4 to day 6+. Nevertheless, the erythema score in IMQ+clobetasol and IMQ+SEL001 was not completely normalized when compared to control group. The total mean scores for erythema and scales are shown in Figures 1A,B, from 0 day to day 6.
FIGURE 1. Erythema and scales score of the dorsal skin of the mice. The scoring was performed on 0 day, 2 day, 4 day, and 6 day using the Psoriasis Area Severity Index (PASI). (A) Erythema score and (B) scales score.
Skin and Ear Thickness
The ear thickness of right ear significantly increased in IMQ and IMQ+vaseline groups. In case of IMQ+clobetasol and IMQ+SEL001, the ear thickness was significantly reduced (Figure 2A). In addition, similar results were seen in dorsal skin thickness. The dorsal skinfold thickness of the mice in IMQ group and IMQ+vaseline showed a significant increase by topical application of IMQ treatment as compared with the intact control group (p < 0.01). The skinfold thickness in IMQ+clobetasol and IMQ+SEL001 group was significantly reduced compared to the IMQ group (p < 0.01) (Figure 2B). Figure 2C shows the visual appearance of IMQ-induced skin after 6 days of treatment. The skinfold thickness and ear thickening in IMQ+clobetasol and IMQ+SEL001 were not completely normalized when compared to control group. Nevertheless, the effect of clobetasol and SEL001 was promising.
FIGURE 2. Caliper measurement and visual appearance of skin. (A) Skin fold thickness on the backs of the mice, (B) right ear thickness, and (C) visual appearance on day 6. Columns represent means ± standard deviation of skin/ear measurements day 6. ∗∗p < 0.001 or ∗p < 0.05 is significant, analyzed by one-way ANOVA test.
A significant increase in epithelial thickness and number of inflammatory cells infiltrated in the dermis of ear tissues were observed in IMQ and IMQ+vaseline group compared to control group (p < 0.01), as shown in Figure 3. In addition, a significant increase in dorsal skin epithelial thickness and the number of inflammatory cells infiltrated in dermis of dorsal skin were also noticed in IMQ group and IMQ+vaseline group as compared with control group (p < 0.01), as shown in Figure 4. Moreover, no significant changes in total dorsal skin thickness and collagen fiber occupied regions in the dermis were observed in the IMQ group and IMQ+vaseline group as compared with the control group, and no significant histopathological changes in the ear and dorsal skin tissues were observed in the IMQ+vaseline group as compared with those of IMQ group. These IMQ-induced hypertensive psoriasis related histopathological changes in both ear and dorsal skin tissues were significantly inhibited in IMQ+clobetasol and IMQ+SEL001 groups (p < 0.01) as shown in Tables 1, 2.
FIGURE 3. Histopathological images of ear tissues of IMQ-induced psoriasis mice. (A) Control, (B) IMQ, (C) IMQ+vaseline, (D) IMQ+clobetasol, and (E) IMQ+SEL001. A noticeable increase of total and epithelial (epidermis) thicknesses, inflammatory cell infiltrations in the dermis, and decreases of dermis collagen fibers were observed in ear tissues of IMQ and IMQ+vaseline as compared with intact control, respectively. However, these IMQ-induced hypersensitive psoriasis related histopathological changes on the ear tissues were significantly inhibited by treatment of test material SEL001 and reference drug clobetasol in the current histopathological inspection. No meaningful histopathological changes in the ear tissues were demonstrated in IMQ+vaseline as compared with those of IMQ control [IMQ = Imiquimod; EP = Epithelium/Epidermis; DM = Dermis; CA = Ear cartilage].
FIGURE 4. Histopathological images of dorsal skin tissues of IMQ-induced psoriasis mice. (A) Control, (B) IMQ, (C) IMQ+vaseline, (D) IMQ+clobetasol, and (E) IMQ+SEL001. Increase of dorsal skin epithelial thickness and inflammatory cell infiltrations in dermis of dorsal skin were noticed in IMQ control and IMQ+vaseline as compared with intact control, respectively. But no significant changes on the dorsal back skin total thicknesses and collagen fiber occupied regions in the dermis were demonstrated in IMQ control and IMQ+vaseline as compared with intact control and no significant histopathological changes in the dorsal skin tissues were demonstrated in IMQ+vaseline as compared with those of IMQ control. These IMQ-induced hypersensitive psoriasis related histopathological changes on the dorsal skin tissues were significantly inhibited by treatment of SEL001 and clobetasol.
TABLE 2. Histomorphometrical analysis of dorsal skin tissues taken from control or IMQ-induced psoriasis mice.
Gene Expression Analysis
Topical treatment of IMQ on the dorsal skin of mice showed an intense change in the gene expression level compared to the intact control, and/or mice treated with IMQ+clobetasol and IMQ+SEL001. The RNA expression analysis indicated an increase in gene expression of IL-19, IL-17A, and IL-23 in the IMQ group when compared with control group a pronounced drop of IL-19 was induced by clobetasol and SEL001 as seen in IMQ+clobetasol and IMQ+SEL001 groups. Similarly, a downregulation of gene expression level of IL-19, IL-17A, and IL-23 was seen in IMQ+clobetasol and IMQ+SEL001 groups compared to IMQ group and IMQ+vaseline group (Figure 5).
FIGURE 5. mRNA expression profile. The data is expressed as mean ± standard deviation, ∗∗p < 0.001 or ∗p < 0.05 is significant, analyzed by one-way ANOVA test.
We have previously shown that L. sakei pro65 has a potent effect against atopic dermatitis both in the mouse model as well as in human clinical trial (Park et al., 2008; Woo et al., 2010). Lactobacillus sakei pro65 significantly reduced the IgE expression level in DNCB induced AD animal model (Kim et al., 2013). Furthermore, in our previous study, we showed L. sakei pro65 extract has antioxidant, anti-diabetic and tyrosinase inhibitory effects (Bajpai et al., 2016). Therefore, this study was designed to evaluate the effect of SEL001 on IMQ-induced psoriasis-like skin inflammation in a mouse model. Interestingly, chemical composition analysis of SEL001 confirmed the presence of various bioactive substances in SEL001, including organic acids, amino acids, phenols, imidazole derivatives, and sugar alcohols. As reported previously, these compounds or SEL001 like products of different origins containing phenolics and organic acids have been found to exhibit significant anti-inflammatory effects in various in vitro and in vivo models (Lee et al., 2006; Beh et al., 2017; Hearps et al., 2017). However, no effective agent has been developed against chronic psoriasis using the probiotic approach, which are known to be Generally Recognized As Safe (GRAS) in nature with no or less adversary effect for human application. Moreover, the SEL001 was found to contain important sugar alcohols, including myo-inositol. It has been reported that myo-inositol has been implicated with curing inflammatory disorders in animal mouse model (Claxson et al., 1990), suggesting that anti-inflammatory effect observed in this study might be mediated through myo-inositol. However, synergistic effects of other active components present in the SEL001 cannot be ruled out. As expected, the application of IMQ resulted in an increase in skin thickness and PASI score for both erythema and scaling. IMQ induced psoriasis model is considered as similar to human psoriasis (Leslie van der et al., 2009; Rather et al., 2016). Nevertheless, it was shown that IMQ induced skin lesions in humans differ to some extent from native psoriasis plaques (Vinter et al., 2015).
In the current histopathological inspection, skin protective effects of SEL001 were observed on the IMQ-induced hypersensitive psoriasis in a mouse model through well-documented histopathology-histomorphometric methods (Qin et al., 2014; Kim et al., 2015a,b; Bai et al., 2016). The results of representative histological profiles and histomorphometric analysis of the ear and dorsal back skin tissues are shown in Figures 3 and 4, respectively.
As reported previously, histopathologically, IMQ-induced hypersensitive psoriasis-like inflammation increased the epidermis hyperplasia and hypertrophy, and dermis inflammatory cell infiltrations in the ear and dorsal skin (van der Fits et al., 2009; Kim et al., 2015a; Bai et al., 2016), and similar results were observed in IMQ and IMQ+vaseline groups in this study. Significant increase of mean total and epidermal thicknesses, numbers of inflammatory cells infiltrated in the dermis, and decrease of dermis collagen fiber occupied regions were observed in the ear tissues of IMQ and IMQ+vaseline groups when compared with the control group. In addition, a significant increase of dorsal skin epithelial thicknesses and number of inflammatory cells infiltrated in the dermis of dorsal back skin were also noticed in IMQ and IMQ+vaseline groups as compared with control group, suggesting classic IMQ-induced hypersensitive psoriasis.
Moreover, no significant changes in the dorsal skin total thicknesses and collagen fiber occupied regions in dermis were demonstrated in IMQ group and IMQ+vaseline group as compared with control group. Also, in the present histopathological measurement, no significant histopathological changes in the tissue of both ear and dorsal skin were observed in IMQ+vaseline group as compared with those of IMQ group, suggesting that vaseline treatment did not show any effect on IMQ-induced hypersensitive psoriasis related histopathology in the ear and dorsal skin tissues. On the other hand, these IMQ-induced hypersensitive psoriasis related histopathological changes in both ear and dorsal skin tissues were significantly inhibited by the treatment of clobetasol and SEL001. Based on histopathological findings, SEL001 has obvious protective effects on the IMQ-induced hypersensitive psoriasis related histopathology in the ear and dorsal skin tissues. The decrease of collagen fibers in the dermis has been indicated edematous changes related to inflammations, as also considered in previous reports (Kim et al., 2015a,b). Decrease in the gene expression of IL-19, IL-17A, and IL-23 levels further confirms the potent effect of SEL001 on IMQ-induced psoriasis.
In summary, in this study, the SEL001 ameliorates the severity of IMQ-induced psoriasis like skin inflammation in mice. Topical application of SEL001 significantly reduced the skin thickening, and improved the erythema and scaling scores. These findings were further supported by improvements in histoclinical symptoms. SEL001 significantly inhibited IMQ-induced skin epithelial thicknesses and dermis inflammatory cell infiltrations. Furthermore, treatment with SEL001 decreased the expression level of psoriasis-associated pro-inflammatory cytokines, such as IL-17A, IL-19, and IL-23, proposing that altogether these changes might be mediators of the positive effects of SEL001 observed in the psoriasis-like skin inflammation model used in this study.
IR and VB performed the experiments and analyzed the data. EB and WP helped in the interpretation of the data. JL and Y-HP participated in the design of the study and the interpretation of the data. IR and VB wrote the manuscript. All authors read and approved the manuscript.
This work was supported by National Research Foundation of Korea (2013M3A9A504705 and 2017M3A9A5048999).
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Bai, S., Zhang, Z., Hou, S., and Liu, X. (2016). Influence of different types of contact hypersensitivity on imiquimod-induced psoriasis-like inflammation in mice. Mol. Med. Rep. 14, 671–680. doi: 10.3892/mmr.2016.5299
Bajpai, V. K., Rather, I. A., and Park, Y. H. (2016). Partially purified exo-polysaccharide from Lactobacillus sakei Probio 65 with antioxidant, α-glucosidase and tyrosinase inhibitory potential. J. Food Biochem. 40, 264–274. doi: 10.1111/jfbc.12230
Beh, B. K., Mohamad, N. E., Yeap, S. K., Ky, H., Boo, S. Y., and Chua, J. Y. H. (2017). Anti-obesity and anti-inflammatory effects of synthetic acetic acid vinegar and Nipa vinegar on high-fat diet-induced obese mice. Sci. Rep. 7:e6664. doi: 10.1038/s41598-017-06235-7
Chapat, L., Chemin, K., Dubois, B., Bourdet-Sicard, R., and Kaiserlian, D. (2004). Lactobacillus casei reduces CD8+ T cell-mediated skin inflammation. Eur. J. Immunol. 34, 2520–2528. doi: 10.1002/eji.200425139
Claxson, A., Morris, C., Blake, D., Sirén, M., Halliwell, B., and Gustafsson, T. (1990). The anti-inflammatory effects of D-myo-inositol-1.2.6-trisphosphate (PP56) on animal models of inflammation. Agents Actions 29, 68–70. doi: 10.1007/BF01964724
El Malki, K., Karbach, S. H., Huppert, J., Zayoud, M., Reisig, S., Schuler, R., et al. (2013). An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J. Invest. Dermatol. 133, 441–451. doi: 10.1038/jid.2012.318
Hacini-Rachinel, F., Nancey, S., Boschetti, G., Sardi, F., Doucet-Ladevèze, R., Pierre-Yves, D., et al. (2009). CD4+ T cells and Lactobacillus casei control relapsing colitis mediated by CD8+ T cells. J. Immunol. 183, 5477–5486. doi: 10.4049/jimmunol.0804267
Hearps, A. C., Tyssen, D., Srbinovski, D., Bayigga, L., Diaz, D. J., and Aldunate, M. (2017). Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal Immunol. 10, 1480–1490. doi: 10.1038/mi.2017.27
Joint FAO/WHO (2001). Expert Committee on Food Additives and World Health Organization. Food & Agriculture Organization. Safety Evaluation of Certain Mycotoxins in Food. Issue 74. Meeting, 2001. Geneva: World Health Organization
Kagami, S., Rizzo, H. L., Lee, J. J., Koguchi, Y., and Blauvelt, A. (2010). Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 130, 1373–1383. doi: 10.1038/jid.2009.399
Kim, C. G., Kang, M., Lee, Y. H., Min, W. G., Kim, Y. H., Kang, S. J., et al. (2015a). Bathing effects of various seawaters on allergic (atopic) dermatitis-like skin lesions induced by 2,4-dinitrochlorobenzene in hairless mice. Evid. Based Complement. Alternat. Med. 2015, 179–185. doi: 10.1155/2015/179185
Kim, K. H., Park, S. J., Lee, Y. J., Lee, J. E., Song, C. H., Choi, S. H., et al. (2015b). Inhibition of UVB-induced skin damage by exopolymers from Aureobasidium pullulans SM-2001 in hairless mice. Basic Clin. Pharmacol. Toxicol. 116, 73–86. doi: 10.1111/bcpt.12288
Kim, H., Rather, I. A., Kim, H., Kim, S., Kim, T., and Jang, J. (2015c). A double-blind, placebo controlled-trial of a probiotic strain Lactobacillus sakei probio-65 for the prevention of canine atopic dermatitis. J. Microbiol. Biotechnol. 25, 1966–1969. doi: 10.4014/jmb.1506.06065
Kim, J. Y., Park, B. K., Park, H. J., Park, Y. H., Kim, B. O., and Pyo, S. (2013). Atopic dermatitis-mitigating effects of new Lactobacillus strain, Lactobacillus sakei probio 65 isolated from Kimchi. J. Appl. Microbiol. 115, 517–526. doi: 10.1111/jam.12229
Lee, E., Trepicchio, W. L., Oestreicher, J. L., Pittman, D., Wang, F., Chamian, F., et al. (2004). Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125–130. doi: 10.1084/jem.20030451
Lee, J. Y., Jang, Y. W., Kang, H. S., Moon, H., Sim, S. S., and Kim, C. J. (2006). Anti-inflammatory action of phenolic compounds from Gastrodia elata root. Arch. Pharm. Res. 29, 849–858. doi: 10.1007/BF02973905
Leslie van der, F., Sabine, M., Jane, S. A. V., Marius, K., Louis, B., Jon, D. L., et al. (2009). Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182, 5836–5845. doi: 10.4049/jimmunol.0802999
Li, H. H., Lin, Y. C., Chen, P. J., Hsiao, C. H., Lee, J. Y., Chen, W. C., et al. (2005). Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br. J. Dermatol. 153, 591–595. doi: 10.1111/j.1365-2133.2005.06665.x
Li, R., Wang, J., Wang, X., Zhou, J., Wang, M., Ma, H., et al. (2016). Increased βTrCP are associated with imiquimod-induced psoriasis-like skin inflammation in mice via NF-κB signaling pathway. Gene 592, 164–171. doi: 10.1016/j.gene.2016.07.066
Matsumoto, S., Hara, T., Hori, T., Mitsuyama, K., Nagaoka, M., and Tomiyasu, N. (2005). Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin. Exp. Immunol. 140, 417–426. doi: 10.1111/j.1365-2249.2005.02790.x
Mudigonda, P., Mudigonda, T., Feneran, A. N., Alamdari, H. S., Sandoval, L., and Feldman, S. R. (2012). Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol. Online J. 18:1.
Nadeem, A., Al-Harbi, N. O., Al-Harbi, M. M., El-Sherbeeny, A. M., Ahmad, S. F., and Siddiqui, N. (2015). Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation. Pharmacol. Res. 99, 248–257. doi: 10.1016/j.phrs.2015.06.001
Park, C. W., Young, M., Jung, Y. M., Kim, H., Jeong, Y., Lee, H. K., et al. (2008). New functional probiotic Lactobacillus sakei probio 65 alleviates atopic symptoms in the mouse. J. Med. Food 11, 405–412. doi: 10.1089/jmf.2007.0144
Park, S. B., Im, M., Lee, Y., Lee, J. H., Lim, J., and Park, Y. H. (2014). Effect of emollients containing vegetable-derived Lactobacillus in the treatment of atopic dermatitis symptoms: split-body clinical trial. Ann. Dermatol. 26, 150–155. doi: 10.5021/ad.2014.26.2.150
Piskin, G., Sylva-Steenland, R. M. R., Bos, J. D., and Teunissen, M. B. M. (2006). In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. 176, 1908–1915. doi: 10.4049/jimmunol.176.3.1908
Plaza-Díaz, J., Ruiz-Ojeda, F. J., Vilchez-Padial, L. M., and Gil, A. (2017). Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases. Nutrients 9:e555. doi: 10.3390/nu9060555
Qin, S., Wen, J., Bai, X. C., Chen, T. Y., Zheng, R. C., Zhou, G. B., et al. (2014). Endogenous n-3 polyunsaturated fatty acids protect against imiquimod-induced psoriasis-like inflammation via the IL-17/IL-23 axis. Mol. Med. Rep. 9, 2097–2104. doi: 10.3892/mmr.2014.2136
Ravi, B., Rentitta, R. E., Pradha, M. L., Issac, R., and Naidu, S. (2013). Evaluation of antidiabetic potential of oyster mushroom (Pleurotus ostreatus) in alloxan-induced diabetic mice. Immunopharmacol. Immunotoxicol. 35, 101–109. doi: 10.3109/08923973.2012.710635
Res, P. C., Piskin, G., de Boer, O. J., van der Loos, C. M., Teeling, P., Bos, J. D., et al. (2010). Overrepresentation of IL-17A and IL- 22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 5:e14108. doi: 10.1371/journal.pone.0014108
Shukla, S., Mehta, A., Mehta, P., and Bajpai, V. K. (2011). Evaluation of comparative antidiabetic effects of ethanol extracts of Caesalpinia bonducella and Stevia rebaudiana in normal and alloxan-induced experimental rats. Rom. Biotechnol. Lett. 16, 6187–6199.
Tojo, R., Suárez, A., Clemente, M. G., De los Reyes-Gavilán, C. G., Margolles, A., and Gueimonde, M. (2014). Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J. Gastroenterol. 20, 15163–15176. doi: 10.3748/wjg.v20.i41.15163
van der Fits, L., Mourits, S., Voerman, J. S., Kant, M., Boon, L., Laman, J. D., et al. (2009). Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182, 5836–5845. doi: 10.4049/jimmunol.0802999
Vinter, H., Iversen, L., Steiniche, T., Kragballe, K., and Johansen, C. (2015). Aldara®-induced skin inflammation: studies of patients with psoriasis. Br. J. Dermatol. 172, 345–353. doi: 10.1111/bjd.13236
Wang, W. J., Yin, X. Y., Zuo, X. B., Cheng, H., Du, W. D., Zhang, F. Y., et al. (2013). Gene-gene interactions in IL23/Th17 pathway contribute to psoriasis susceptibility in Chinese Han population. J. Eur. Acad. Dermatol. Venereol. 27, 1156–1162. doi: 10.1111/j.1468-3083.2012.04683.x
Wolf, R., Howard, O. M., Dong, H. F., Voscopoulos, C., Boeshans, K., and Winston, J. (2008). Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J. Immunol. 181, 1499–1506. doi: 10.4049/jimmunol.181.2.1499
Woo, S. I., Kim, J. Y., Lee, Y. J., Kim, N. S., and Hahn, Y. S. (2010). Effect of Lactobacillus sakei supplementation in children with atopic eczema-dermatitis syndrome. Ann. Allery Asthama Immunol. 104, 343–348. doi: 10.1016/j.anai.2010.01.020
Wu, C.-S., Chui, W.-H., Chen, Y.-H., Chao, Y.-H., Lin, C.-C., Li, Y.-R., et al. (2017). Lactobacillus pentosus GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-like mice. J. Dermatol. Sci. 86, e17–e18. doi: 10.1016/j.jdermsci.2017.02.050
Yoo, I. S., Lee, J. H., Song, S. T., Kim, J. H., Lee, H. J., and Kang, S. W. (2012). T-helper 17 cells: the driving force of psoriasis and psoriatic arthritis. Int. J. Rheum. Dis. 15, 531–537. doi: 10.1111/j.1756-185X.2012.01813.x
Zhang, L., Yang, X. Q., Cheng, J., Hui, R. S., and Gao, T. W. (2010). Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clin. Immunol. 135, 108–117. doi: 10.1016/j.clim.2009.11.008
Keywords: psoriasis, skin inflammation, Lactobacillus sakei, lactic acid bacteria, imiquimod
Citation: Rather IA, Bajpai VK, Huh YS, Han Y-K, Bhat EA, Lim J, Paek WK and Park Y-H (2018) Probiotic Lactobacillus sakei proBio-65 Extract Ameliorates the Severity of Imiquimod Induced Psoriasis-Like Skin Inflammation in a Mouse Model. Front. Microbiol. 9:1021. doi: 10.3389/fmicb.2018.01021
Received: 08 August 2017; Accepted: 30 April 2018;
Published: 17 May 2018.
Edited by:Philippe Langella, Institut National de la Recherche Agronomique (INRA), France
Reviewed by:Benoit Chassaing, Georgia State University, United States
Laura Bonifaz, Instituto Mexicano del Seguro Social (IMSS), Mexico
Ronald Sluyter, University of Wollongong, Australia
Copyright © 2018 Rather, Bajpai, Huh, Han, Bhat, Lim, Paek and Park. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
†These authors have contributed equally to this work.